{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T05:04:47Z","timestamp":1771563887886,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005492","name":"Stanford University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014549","name":"Stanford Cancer Institute","doi-asserted-by":"publisher","award":["P30CA124435"],"award-info":[{"award-number":["P30CA124435"]}],"id":[{"id":"10.13039\/100014549","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.leukres.2025.107736","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T12:24:17Z","timestamp":1751372657000},"page":"107736","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Molecular taxonomy of MDS\/CMML patients influences responses to hypomethylating agents and clinical outcomes"],"prefix":"10.1016","volume":"156","author":[{"given":"Alfonso","family":"Molina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishesh","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandria","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henning","family":"Stehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Yatsenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter L.","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.leukres.2025.107736_bib1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.leukres.2025.107736_bib2","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2025.107736_bib3","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.leukres.2025.107736_bib4","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","article-title":"Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia","volume":"121","author":"Such","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2025.107736_bib5","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.leukres.2011.09.007","article-title":"Time changes in predictive power of established and recently proposed clinical, cytogenetical and comorbidity scores for Myelodysplastic Syndromes","volume":"36","author":"Pfeilst\u00f6cker","year":"2012","journal-title":"Leuk. Res"},{"issue":"3","key":"10.1016\/j.leukres.2025.107736_bib6","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/sj.leu.2405070","article-title":"A prognostic score for patients with lower risk myelodysplastic syndrome","volume":"22","author":"Garcia-Manero","year":"2008","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.leukres.2025.107736_bib7","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid."},{"issue":"11","key":"10.1016\/j.leukres.2025.107736_bib8","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1200\/JCO.20.01659","article-title":"Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes","volume":"39","author":"Bersanelli","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"33","key":"10.1016\/j.leukres.2025.107736_bib9","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.20.02810","article-title":"Personalized prediction model to risk stratify patients with myelodysplastic syndromes","volume":"39","author":"Nazha","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2025.107736_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2023.107433","article-title":"The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms","volume":"136","author":"Khanna","year":"2024","journal-title":"Leuk. Res."},{"issue":"15","key":"10.1016\/j.leukres.2025.107736_bib11","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood.2023023727","article-title":"Molecular taxonomy of myelodysplastic syndromes and its clinical implications","volume":"144","author":"Bernard","year":"2024","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.leukres.2025.107736_bib12","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"10399","key":"10.1016\/j.leukres.2025.107736_bib13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(23)00874-7","article-title":"Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial","volume":"402","author":"Platzbecker","year":"2023","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.leukres.2025.107736_bib14","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/bloodadvances.2018020495","article-title":"Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes","volume":"2","author":"Itzykson","year":"2018","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.leukres.2025.107736_bib15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ajh.24930","article-title":"Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management","volume":"93","author":"Montalban-Bravo","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.leukres.2025.107736_bib16","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1111\/bjh.16615","article-title":"Distinct bone marrow morphologic features discriminate myelodysplastic syndromes patients with and without an early platelet response to decitabine","volume":"189","author":"May","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2025.107736_bib17","first-page":"3","article-title":"Genomic biomarkers to predict resistance to hypomethylating agents in patients with myelodysplastic syndromes using artificial intelligence","author":"Nazha","year":"2019","journal-title":"JCO Precis Oncol."},{"issue":"7","key":"10.1016\/j.leukres.2025.107736_bib18","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/leu.2011.71","article-title":"Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias","volume":"25","author":"Itzykson","year":"2011","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.leukres.2025.107736_bib19","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","article-title":"TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients","volume":"124","author":"Bejar","year":"2014","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.leukres.2025.107736_bib20","doi-asserted-by":"crossref","first-page":"18845","DOI":"10.18632\/oncotarget.4586","article-title":"Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing?","volume":"6","author":"Peterson","year":"2015","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.leukres.2025.107736_bib21","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cancergen.2011.10.004","article-title":"Microarray-based comparative genomic hybridization of cancer targets reveals novel, recurrent genetic aberrations in the myelodysplastic syndromes","volume":"204","author":"Kolquist","year":"2011","journal-title":"Cancer Genet."},{"issue":"10","key":"10.1016\/j.leukres.2025.107736_bib22","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat. Med."},{"issue":"17","key":"10.1016\/j.leukres.2025.107736_bib23","first-page":"2047","article-title":"Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes","volume":"141","author":"Zeidan","year":"2023","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.leukres.2025.107736_bib24","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2025.107736_bib25","unstructured":"Rodriguez A., Dunson D.B., Gelfand A.E. Bayesian nonparametric functional data analysis through density estimation."},{"key":"10.1016\/j.leukres.2025.107736_bib26","first-page":"1551","article-title":"A bayesian model for supervised clustering with the dirichlet process prior","volume":"6","author":"Daume","year":"2005","journal-title":"J. Mach. Learn Res"},{"issue":"22","key":"10.1016\/j.leukres.2025.107736_bib27","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2025.107736_bib28","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1038\/s41467-022-32103-8","article-title":"Unified classification and risk-stratification in Acute Myeloid Leukemia","volume":"13","author":"Tazi","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.leukres.2025.107736_bib29","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1038\/s41467-018-06063-x","article-title":"Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia","volume":"9","author":"Shiozawa","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.leukres.2025.107736_bib30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the False discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. Ser. B (Methodol.)"},{"issue":"11","key":"10.1016\/j.leukres.2025.107736_bib31","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1002\/ajh.27070","article-title":"Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants","volume":"98","author":"Bataller","year":"2023","journal-title":"Am. J. Hematol."},{"issue":"8","key":"10.1016\/j.leukres.2025.107736_bib32","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026518","article-title":"TET2 in normal and malignant hematopoiesis","volume":"7","author":"Bowman","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"10","key":"10.1016\/j.leukres.2025.107736_bib33","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200034","article-title":"Low-dose decitabine versus low-dose azacitidine in lower-risk MDS","volume":"1","author":"Sasaki","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.leukres.2025.107736_bib34","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood-2021-146932","article-title":"Ivosidenib monotherapy is effective in patients with IDH1 mutated myelodysplastic syndrome (MDS): the idiome phase 2 study by the GFM group","volume":"138","author":"Sebert","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107736_bib35","doi-asserted-by":"crossref","first-page":"S366","DOI":"10.1016\/S2152-2650(23)01189-8","article-title":"MDS-457 ivosidenib in mutant IDH1 relapsed\/refractory myelodysplastic syndrome: updated substudy results","volume":"23","author":"DiNardo","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"Supplement 1","key":"10.1016\/j.leukres.2025.107736_bib36","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-147898","article-title":"Enasidenib (ENA) is effective in patients with IDH2 mutated myelodysplastic syndrome (MDS): the ideal phase 2 study by the GFM group","volume":"138","author":"Ades","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2025.107736_bib37","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/bloodadvances.2022008378","article-title":"Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome","volume":"7","author":"DiNardo","year":"2023","journal-title":"Blood Adv."},{"issue":"24","key":"10.1016\/j.leukres.2025.107736_bib38","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1200\/JCO.23.02175","article-title":"Clinical and genomic-based decision support system to define the optimal timing of allogeneic hematopoietic stem-cell transplantation in patients with myelodysplastic syndromes","volume":"42","author":"Tentori","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2025.107736_bib39","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41375-023-01820-4","article-title":"Outcome prediction in myelodysplastic neoplasm undergoing hematopoietic cell transplant in the molecular era of IPSS-M","volume":"37","author":"Gurnari","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2025.107736_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2024.107529","article-title":"Molecular prognostication for transplant decision making of patients with myelodysplastic syndromes: a retrospective single-center study","volume":"142","author":"Condorelli","year":"2024","journal-title":"Leuk. Res"},{"issue":"1","key":"10.1016\/j.leukres.2025.107736_bib41","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1038\/s41467-023-38515-4","article-title":"Molecular patterns identify distinct subclasses of myeloid neoplasia","volume":"14","author":"Kewan","year":"2023","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.leukres.2025.107736_bib42","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1007\/s00277-018-3464-9","article-title":"Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes","volume":"97","author":"Wang","year":"2018","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2025.107736_bib43","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719847059","article-title":"Management of myelodysplastic syndromes after failure of response to hypomethylating agents","volume":"10","author":"Gil-Perez","year":"2019","journal-title":"Ther. Adv. Hematol."},{"issue":"4","key":"10.1016\/j.leukres.2025.107736_bib44","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3324\/haematol.2013.099549","article-title":"Why methylation is not a marker predictive of response to hypomethylating agents","volume":"99","author":"Voso","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.leukres.2025.107736_bib45","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1038\/s41467-021-23186-w","article-title":"RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis","volume":"12","author":"Carr","year":"2021","journal-title":"Nat. Commun."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625000967?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625000967?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T13:56:27Z","timestamp":1756821387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212625000967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":45,"alternative-id":["S0145212625000967"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107736","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular taxonomy of MDS\/CMML patients influences responses to hypomethylating agents and clinical outcomes","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107736","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107736"}}